{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "HROW",
  "name": "Harrow, Inc.",
  "url": "https://frontierpicks.com/dossiers/HROW/",
  "json_url": "https://frontierpicks.com/dossiers/HROW.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Post-Q2 this is a leverage-and-execution show-me: the reaffirmed $350–365M FY guide needs H2 to roughly double the $114.9M booked in H1, against $292.4M loans payable net and $14.8M equity. The 2026-08-20 IHEEZO comfort data supports the retina volume leg but resolves none of that, and no company-confirmed catalyst lands before the ~November Q3 print.",
  "invalidation_trigger": "A weekly close below $36 erases the post-Q2 stabilisation and leaves the mid-May reaction low near $34 as the next reference; secondary break is any cut to the reaffirmed $350–365M FY2026 revenue or $80–100M adjusted EBITDA guide at or before the Q3 print.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Leverage: loans payable net $292.4M vs $83.9M cash and $14.8M stockholders' equity at 2026-06-30 — a thin equity cushion makes the name rate- and refinancing-sensitive.",
    "FY2026 guide is H2-weighted by construction: H1 revenue $114.9M against a reaffirmed $350–365M full-year range.",
    "Commercial ophthalmology specialty pharma (VEVYE/IHEEZO/TRIESENCE/VERKAZIA plus biosimilars BYOOVIZ/OPUVIZ), not a clinical-stage or gene-therapy biotech.",
    "TYRVAYA purchase pending: $30M cash at closing plus up to $70M in sales milestones, expected H2 2026 with no closing date disclosed (2026-08-06).",
    "VEVYE gross-to-net adjustments have moved reported revenue before (~$8M in Q1 2026); the GTN line is worth reading in every release.",
    "ImprimisRx compounding revenue is contracting — $14.6M in Q2 2026 vs $21.5M a year earlier — offsetting branded growth in the total."
  ],
  "body_markdown": "## Current Thesis\n\nTwo weeks past the Q2 print, nothing has arrived that resolves the arithmetic the print created. Revenue of $70.661M on 2026-08-10 landed below the company's own $71–81M guidance floor, and FY2026 guidance was reaffirmed anyway at $350–365M revenue with $80–100M adjusted EBITDA. Against H1 revenue of $114.9M, that leaves $235–250M for the back half — INFERRED from the two disclosed figures, not a company statement — while adjusted EBITDA has to travel from Q1 $(12.7)M and Q2 $(1.2)M to a guided full-year $80–100M. The equity is pricing that swing against a balance sheet carrying $292.4M loans payable net, $83.9M cash and $14.8M of stockholders' equity at 2026-06-30, with $30M more due at the TYRVAYA close.\n\nWhat is new since the last update is narrow and clinical. On 2026-08-20 Harrow released a prospective, randomized, contralateral-eye study in 50 patients (100 eyes) undergoing same-day bilateral intravitreal injections: patients reported approximately 58% less overall discomfort in the IHEEZO-treated eye than in the fellow eye given proparacaine 0.5%, statistically significant at all four post-injection assessments (all p≤0.048). Both eyes received 2% lidocaine-soaked pledgets first, so the comparison is IHEEZO versus a topical drop on top of a common base. That supports the retina channel behind IHEEZO's 65,477 Q2 units (+44% sequentially, +34% YoY), and it is a 50-patient patient-reported-comfort study — no label change, no reimbursement decision.\n\n**The narrative is maturing.** Dated by 2026-08-10, when the print that had driven the tape since June cleared without a re-rate, and by the week of 2026-08-17: fresh clinical data on 08-20 plus Buy reiterations from Lake Street and William Blair (2026-08-20) and BTIG (2026-08-21) produced a 2026-08-21 close of $40.95 against $40.03 on 2026-08-14. Well known, still working — the shares are up 24.1% over three months — with the incremental headline bid reduced to a $30M bolt-on, a comfort study and maintained ratings.\n\n## Bull Case\n\n- **The sequential ramp is real in units.** Q2 revenue $70.661M versus $44.2M in Q1 (+~60% QoQ, +11% YoY, 2026-08-10). VEVYE posted record quarterly revenue of $29.4M (+58% YoY); TRIESENCE 14,529 units (+162% YoY).\n- **The 2026-08-20 IHEEZO data addresses the exact use case driving unit growth.** Retina practices repeat intravitreal injections over years; a statistically significant discomfort reduction (p≤0.048 at all four timepoints) gives the salesforce a controlled comparison against the incumbent topical anesthetic, alongside the BYOOVIZ/OPUVIZ push into the same offices.\n\n- **Sell-side coverage is uniformly constructive.** Eight analysts, all Buy, consensus target $67.50 with a $59–$88 range (stockanalysis.com, 2026-08-23), versus the 2026-08-21 close of $40.95. BTIG's $63 target was reiterated on 2026-08-11.\n\n## Bear Case\n\n- **The company missed its own floor.** $70.661M against $71–81M guided (2026-08-10). Consensus at $70.342M had already drifted under the guidance midpoint, which is why the print moved little.\n- **The EBITDA guide requires a step no quarter has yet shown.** H1 adjusted EBITDA was negative in both quarters; the reaffirmed $80–100M annual range implies an H2 run-rate the business has not printed since Q2 2025's $17.0M.\n- **Margin is going the wrong way.** Gross margin 71% in Q2 2026 versus 75% a year earlier, with the mix shifting toward biosimilars.\n- **The legacy leg is shrinking.** ImprimisRx compounding revenue $14.6M in Q2 2026 versus $21.5M a year earlier, offsetting branded growth inside the consolidated line.\n- **Thin equity cushion.** $14.8M of stockholders' equity against $292.4M loans payable net at 2026-06-30, with $30M of cash committed at the TYRVAYA close and H1 operating cash flow of $(18.7)M.\n- **Unanimous ratings are a positioning observable, not a support.** With 8 of 8 covering analysts at Buy and the shares 25.3% below the $54.80 52-week high, revisions from here can only travel in one direction — an inference from the coverage distribution, not a forecast.\n\n## Setup & Price Structure\n\nThe 2026-08-21 close was $40.95, 25.3% under the $54.80 52-week high, with a three-month price change of +24.1% and RSI(14) at 59.6 — mid-range, neither washed out nor extended. The post-print behaviour is the structure that matters: the shares held the low-$40s through the 08-10 miss-versus-guide, the 08-20 clinical release and three Buy maintains, closing higher week-on-week ($40.03 on 2026-08-14 to $40.95 on 2026-08-21) without reclaiming anything near the high. That is consolidation, and it has been in place for roughly two weeks — too short a window to call a base formed.\n\nReference levels: $36 marks the floor of the post-Q2 stabilisation range; below it the mid-May reaction low near $34 becomes the next visible reference. On the upside there is no dated event to price against until the Q3 report.\n\nCrowding evidence, stated as observables: all eight covering analysts carry Buy ratings with a $67.50 consensus target (2026-08-23); three of them reiterated inside 48 hours of the 08-20 data; the gap between that consensus and the $40.95 close is roughly 65%. No insider transactions have surfaced in the filings window since the print — a 2026-05-28 Benzinga piece flagged joint CEO/CFO buying earlier in the year, which is a headline about past filings and says nothing about current activity. No equity issuance or ATM drawdown has been disclosed since the 10-Q.\n\n## Catalyst Calendar (next 30 days)\n\n- **Nothing company-confirmed falls in the 2026-08-23 → 2026-09-22 window.** No earnings date, no PDUFA, no announced conference presentation.\n- **~2026-12-31 (est.) — TYRVAYA closing.** Guided to H2 2026 with no date disclosed (2026-08-06). The first observable will be an 8-K; it triggers the $30M cash payment and starts consolidation of TYRVAYA revenue.\n- **~2026-11-09 (est.) — Q3 2026 results.** Not company-confirmed. First quarter of the H2 ramp the reaffirmed guide requires and the first full quarter of BYOOVIZ.\n\n## What Would Change Our Mind\n\nThe structure to watch is the low-$40s shelf that has absorbed the guidance miss, the clinical release and the ratings reiterations. Losing it takes the story back to the pre-print range: a weekly close below $36 erases the post-Q2 stabilisation and leaves the mid-May reaction low near $34 as the next reference. On the fundamentals, any cut to the $350–365M revenue or $80–100M adjusted EBITDA range at or before the Q3 report ends the reaffirmation as a support for the tape. A financing that arrives before the H2 ramp is visible — an equity offering, ATM drawdown or new debt in an 8-K or prospectus supplement — changes the leverage picture directly. And if the TYRVAYA close slips past year-end, the H2 guidance that assumed a contribution from it loses a piece.\n\nThe read improves on the reverse: a Q3 print showing the sequential revenue step the guide implies, with adjusted EBITDA positive by a meaningful margin, converts the arithmetic problem into a delivered ramp.\n\n## Correlation Notes\n\n- **Rate and credit sensitivity dominates the beta here.** $292.4M loans payable net against $14.8M of equity makes the equity a residual claim on refinancing conditions; it will trade with small-cap credit spreads more than with drug-development sentiment.\n- **Not a clinical-stage comp.** This is commercial ophthalmology specialty pharma (VEVYE, IHEEZO, TRIESENCE, VERKAZIA, plus BYOOVIZ/OPUVIZ biosimilars), so XBI-style binary-readout correlation is a poor frame; revenue is buy-and-bill and pharmacy-channel dependent.\n- **Physician-office reimbursement policy is a shared factor.** IHEEZO and TRIESENCE revenue runs through in-office procedural economics; any change to that reimbursement framework hits the same line items that drove the Q2 unit records.\n- **Counterparty links.** Viatris on TYRVAYA until the deal closes; Samsung Bioepis on BYOOVIZ and OPUVIZ supply. Both are external dependencies on revenue lines the FY guide leans on.\n- **Dry-eye competitive set.** VEVYE and TYRVAYA both sell into a market with entrenched branded competition, so pricing news from that category reads across to Harrow's gross-to-net line.",
  "first_seen": "2026-06-18",
  "last_analyzed": "2026-08-23T13:12:15+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}